Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Hum Mutat. 2017 Dec;38(12):1723-1730. doi: 10.1002/humu.23320. Epub 2017 Sep 21.
Li-Fraumeni syndrome (LFS) is an autosomal-dominant cancer predisposition disorder associated with pathogenic germline variants in TP53, with a high penetrance over an individual's lifetime. The actual population prevalence of pathogenic germline TP53 mutations is still unclear, most likely due to biased selection of cancer affected families. The aim of this study was to estimate the population prevalence of potentially pathogenic TP53 exonic variants in three sequencing databases, totaling 63,983 unrelated individuals. Potential pathogenicity was defined using an original algorithm combining bioinformatic prediction tools, suggested clinical significance, and functional data. We identified 34 different potentially pathogenic TP53 variants in 131 out of 63,983 individuals (0.2%). Twenty-eight (82%) of these variants fell within the DNA-binding domain of TP53, with an enrichment for specific variants that were not previously identified as LFS mutation hotspots, such as the p.R290H and p.N235S variants. Our findings reveal that the population prevalence of potentially pathogenic TP53 variants may be up to 10 times higher than previously estimated from family-based studies. These results point to the need for further studies aimed at evaluating cancer penetrance modifiers as well as the risk associated between cancer and rare TP53 variants.
李-佛美尼综合征(Li-Fraumeni syndrome,LFS)是一种常染色体显性遗传的癌症易感性疾病,与 TP53 种系致病性变异相关,具有个体终身的高外显率。致病性种系 TP53 突变的实际人群流行率仍不清楚,这很可能是由于对癌症相关家族的选择性偏倚。本研究的目的是在三个测序数据库中估计潜在致病性 TP53 外显子变异的人群流行率,共涉及 63983 名无亲缘关系的个体。潜在致病性是使用一种原始算法来定义的,该算法结合了生物信息学预测工具、提示临床意义和功能数据。我们在 63983 名个体中的 131 名个体中发现了 34 种不同的潜在致病性 TP53 变异(0.2%)。其中 28 种(82%)变异位于 TP53 的 DNA 结合域内,且存在特定变异的富集,这些变异以前并未被确定为 LFS 突变热点,例如 p.R290H 和 p.N235S 变异。我们的发现表明,潜在致病性 TP53 变异的人群流行率可能比以前基于家族研究的估计高 10 倍。这些结果表明需要进一步研究,以评估癌症外显率修饰因子以及癌症与罕见 TP53 变异之间的关联风险。